Biomedical Systems teams up with Foundry Health for real-time trial data

Clinical study provider Biomedical Systems has formed a new collab with digital health company Foundry to be able to help pharma, biotech and CRO clients view trial data in real-time.

The two said in a joint statement that they will work on a cloud-based data management system that will allow sponsors “immediate access to clinical trial data” in real time.

“We’ve been a leader in the clinical trials industry for more than 40 years, and we continue to invest in technologies that improve data management capabilities for our clients,” said Tim Barrett, CEO, Biomedical Systems.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Our partnership with Foundry Health will result in a best-in-class data management solution, and we are dedicating significant resources to accelerate its availability.”

Brock Heinz, CEO, Foundry Health, added: “The partnership with Biomedical Systems will provide clients a continuum of data management for all phases of study.

“Biomedical Systems will focus on applications in phases two through four, while Foundry Health will continue to service clients, concentrating on phase one. We believe the product we are developing together will ultimately transform the way data is managed and accessed within clinical trials.”

Biomedical said the new system will be “phased in over time” but will eventually be made available to all of its clients. A timeline of this process, or financial details of the collab, were not given.

- check out the release

Related Articles:
Medtronic backs stealthy Foundry startup as it nabs $7.5M for novel remote patient monitoring
Stealth Foundry grad Twelve racks up $35M for percutaneous mitral valve replacement


Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.